High level of ANO1 promotes pancreatic cancer growth in concert with oncogenic KRAS
- 30 January 2023
- journal article
- research article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (4) , 3297-3307
Abstract
Background Anoctamin-1 (ANO1) was identified as an unfavorable prognostic marker in pancreatic cancer. However, the exact implication of ANO1 in pancreatic cancer is still poorly understood. Here we investigated the effect of ANO1 in pancreatic cancer progression under the context of oncogenic KRAS, aiming at finding a new therapeutic target. Methods Knockdown and overexpression of oncogenic KRAS as well as ANO1 in PDAC cell lines were performed by lentivirus infection. Cell proliferation and migration assay, RNA seq analysis were performed in PDAC cells bearing different status of ANO1 and KRAS. In vivo mice model was used to investigate the xenograft tumor growth with different status of KRAS and ANO1. Results Our results showed that ANO1 expression level is elevated in poorly differentiated cancer cells. Overexpression of ANO1 in PDAC cancer cells was found to promote cancer cell proliferation in vitro and in vivo, which synergized with the introduction of oncogenic KRAS. Consistently, knockdown of ANO1 expression was found to suppress cancer growth in vitro and in vivo. RNA seq analysis revealed that the observed synergistic cancer-promoting effect from ANO1 and oncogenic KRAS is likely due to concurrent activating key genes involved in lipid metabolism including HMGCS1. Conclusion The outcome from our study suggests that ANO1 plays an important role in promoting pancreatic cancer development, especially at the presence of oncogenic KRAS. Considering the prevalence of KRAS mutation in pancreatic cancer patients, suppression ANO1 may represent a potential effective therapeutic measure in pancreatic cancer treatment.Keywords
Funding Information
- Youth Science Fund Project (81601234)
- the Science and Technology Research Project of Jilin Provincial Education Department (JJKH20210484KJ, JJKH20210500KJ)
- the Health Science and Technology Innovation Project of Jilin Province (20192C005)
- the Science and Technology Planning Project of Jilin Province (20200404099YY)
This publication has 24 references indexed in Scilit:
- ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC)Pflügers Archiv - European Journal of Physiology, 2014
- Functional role of the Ca2+-activated Cl− channel DOG1/TMEM16A in gastrointestinal stromal tumor cellsExperimental Cell Research, 2014
- TMEM16A alternative splicing coordination in breast cancerMolecular Cancer, 2013
- Roles for KRAS in Pancreatic Tumor Development and ProgressionGastroenterology, 2013
- Inhibition of Ca2+-activated Cl− channel ANO1/TMEM16A expression suppresses tumor growth and invasiveness in human prostate carcinomaCancer Letters, 2012
- Enhanced Expression of ANO1 in Head and Neck Squamous Cell Carcinoma Causes Cell Migration and Correlates with Poor PrognosisPLOS ONE, 2012
- TMEM16A Inhibitors Reveal TMEM16A as a Minor Component of Calcium-activated Chloride Channel Conductance in Airway and Intestinal Epithelial CellsJournal of Biological Chemistry, 2011
- TMEM16A, A Membrane Protein Associated with Calcium-Dependent Chloride Channel ActivityScience, 2008
- Small-Molecule Screen Identifies Inhibitors of a Human Intestinal Calcium-Activated Chloride ChannelMolecular Pharmacology, 2008
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in miceCancer Cell, 2005